Humabiologics is a Phoenix-based regenerative medicine company making human biomaterials more accessible to scientists, clinicians and product developers in regenerative medicine, tissue engineering, bioprinting, organoids, disease modeling and drug discovery. Our mission is to give researchers more human-relevant building blocks to develop better therapies and more predictive models of human biology. Many platforms still rely on animal materials and animal testing, even when the goal is to treat human patients. Humabiologics helps close that gap by producing native human collagen, gelatin, extracellular matrix products, bioinks and related biomaterials.
Since our founding, we have grown from an early-stage Phoenix startup into a revenue-generating company serving academic, biotech, pharmaceutical and medical device customers worldwide. Our products are used by more than 150 labs and companies in approximately 25 countries, and our portfolio has expanded to roughly 70 human-derived biomaterial products. We have also built quality and manufacturing capabilities that support research and translational development.
A meaningful sign of our impact is that our materials now support clinical-stage regenerative medicine programs, including advanced ophthalmology work where 3D-bioprinted corneal tissue is being implanted in patients with serious vision loss.
Humabiologics has also secured many issued patents covering important processes for producing human-derived collagen and gelatin biomaterials.
Synergy in the Ecosystem
Humabiologics fits into the Greater Phoenix bioscience ecosystem as both a life science manufacturer and an enabling technology company. Our products support researchers, biotech companies, pharmaceutical companies and medical device developers building the next generation of healthcare solutions. Phoenix has been a strong place to build because the region offers healthcare systems, universities, engineering talent, entrepreneurs, suppliers and economic development organizations that understand the needs of growing life science companies.
While providing access to talent, healthcare institutions, universities and business infrastructure, Greater Phoenix remains connected enough for entrepreneurs to build meaningful relationships. For Humabiologics, Phoenix has provided the foundation to build a company rooted in Arizona while serving customers globally.
Humabiologics also collaborates beyond Arizona when needed. Through the National Science Foundation-funded Piedmont Triad Regenerative Medicine Engine, led by the Wake Forest Institute for Regenerative Medicine, Humabiologics is helping advance human collagen matrix technologies for wound healing and soft tissue regeneration. This shows how strong local ecosystems can connect to national research and commercialization networks.
Synergy is not a luxury in bioscience; it is a requirement. New therapies require scientific discovery, regulatory expertise, manufacturing, clinical input, funding, talent and specialized infrastructure.
The Now & Future Biosciences Hub
I view Greater Phoenix as an emerging and increasingly credible hub for biotech and bioscience. The pieces are coming together: healthcare systems, research institutions, universities, entrepreneurs, investors, accelerators, advanced manufacturing capabilities and public-sector support. Phoenix is becoming a place where bioscience companies can be built.
Bioscience is exactly the kind of sector Greater Phoenix should continue to prioritize. These are high-skill, high-wage jobs that create demand for quality manufacturing, logistics, engineering, software, professional services and healthcare infrastructure. Companies also create long-term economic value through intellectual property, advanced manufacturing and products that can reach national and international markets. Humabiologics is one example: We are building patented technologies, manufacturing human biomaterials in Phoenix, selling products worldwide and supporting clinical-stage innovation from Arizona.
What is helping most is the region’s willingness to invest in bioscience infrastructure and bring universities, hospitals, entrepreneurs, government and economic development organizations together around a shared vision. What would help even more is continued investment in wet lab space, scale-up manufacturing facilities, specialized workforce training and local sources of growth capital for life science companies. Phoenix has many ingredients needed to become a nationally recognized bioscience hub. The next stage is making sure companies that start here can also scale here. Humabiologics is proud to be part of that story: building in Phoenix, serving the world and helping advance better tools, therapies and outcomes for patients.
Mohammad Albanna, Ph.D.
Founder & CEO
Humabiologics
Read all the bioindustry stories.
